Lemaitre Vascular (LMAT) Enterprise Value (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Enterprise Value data on file, last reported at -$367.2 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 21.38% year-over-year to -$367.2 million in Q1 2026; TTM through Mar 2026 was -$367.2 million, a 21.38% decrease from a year earlier, with the FY2025 full-year figure at -$359.1 million, down 19.82% from the prior year.
• Enterprise Value for Q1 2026 stood at -$367.2 million, down from -$359.1 million in the prior quarter.
• Over the last five years, Enterprise Value for LMAT reached as high as -$70.9 million in Q1 2022 and fell as low as -$367.2 million in Q1 2026.
• Historically, Enterprise Value has averaged -$177.6 million across 5 years, with a median of -$108.3 million in 2024.
• Across the five-year window, Enterprise Value slumped 247.87% in 2022 and fell 14.28% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$82.7 million in 2022, then fell by 27.07% to -$105.1 million in 2023, then slumped by 185.25% to -$299.7 million in 2024, then declined by 19.82% to -$359.1 million in 2025, then declined by 2.26% to -$367.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$367.2 million in Q1 2026, -$359.1 million in Q4 2025, and -$343.1 million in Q3 2025.